1 BTC
=
- USD
Agilent Technologies Inc.
As of August 26, 2026 at 00:03 UTC
Chart
About Agilent Technologies Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
A in Bitcoin terms
Agilent Technologies Inc. is tracked on Roxom Terminal for users who want to follow and trade global stocks in a Bitcoin-denominated market environment.
- Agilent Technologies Inc. is categorized under LABORATORY ANALYTICAL INSTRUMENTS.
- BTC-denominated charting frames stock performance against Bitcoin instead of fiat alone.
- The global terminal hub links individual stock pages into a crawlable BTC-native market map.
Market Statistics
Trading Metrics
How to Buy A
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy A
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe global gRNA (guide RNA) market is projected to grow from USD 518 million in 2024 to USD 2,950 million by 2034, representing a 19% CAGR. Growth is driven by increasing cancer research, infectious disease prevalence, technological innovation, and expanding applications in genome editing, functional genomics, diagnostics, cell & gene therapy, and agricultural biotechnology. Key market players include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, and others. Strategic partnerships and rising adoption of CRISPR technology in agriculture are major growth catalysts.
Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.
The global mass spectrometry market is valued at $6.68 billion in 2025 and is projected to reach $14.09 billion by 2035, growing at a CAGR of 7.74%. Growth is driven by pharmaceutical manufacturing, omics research, clinical diagnostics, and precision medicine adoption. North America leads the market while Asia Pacific records the fastest growth at 9.12% CAGR.
The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment growth, while Asia-Pacific emerges as the fastest-growing region. Key players include Roche, Thermo Fisher, Illumina, and Agilent Technologies.
The global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.
